» Articles » PMID: 33507222

Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement

Abstract

Importance: There is currently no guidance on how to approach surveillance mammography for older breast cancer survivors, particularly when life expectancy is limited.

Objective: To develop expert consensus guidelines that facilitate tailored decision-making for routine surveillance mammography for breast cancer survivors 75 years or older.

Evidence: After a literature review of the risk of ipsilateral and contralateral breast cancer events among breast cancer survivors and the harms and benefits associated with mammography, a multidisciplinary expert panel was convened to develop consensus guidelines on surveillance mammography for breast cancer survivors 75 years or older. Using an iterative consensus-based approach, input from clinician focus groups, and critical review by the International Society for Geriatric Oncology, the guidelines were refined and finalized.

Findings: The literature review established a low risk for ipsilateral and contralateral breast cancer events in most older breast cancer survivors and summarized the benefits and harms associated with mammography. Draft mammography guidelines were iteratively evaluated by the expert panel and clinician focus groups, emphasizing a patient's risk for in-breast cancer events, age, life expectancy, and personal preferences. The final consensus guidelines recommend discontinuation of routine mammography for all breast cancer survivors when life expectancy is less than 5 years, including those with a history of high-risk cancers; consideration to discontinue mammography when life expectancy is 5 to 10 years; and continuation of mammography when life expectancy is more than 10 years. Individualized, shared decision-making is encouraged to optimally tailor recommendations after weighing the benefits and harms associated with surveillance mammography and patient preferences. The panel also recommends ongoing clinical breast examinations and diagnostic mammography to evaluate clinical findings and symptoms, with reassurance for patients that these practices will continue.

Conclusions And Relevance: It is anticipated that these expert guidelines will enhance clinical practice by providing a framework for individualized discussions, facilitating shared decision-making regarding surveillance mammography for breast cancer survivors 75 years or older.

Citing Articles

Use of surveillance mammography among older patients with a history of breast cancer.

Berger E, Long J, Sheffrin M, Lindsay M, Richman I J Geriatr Oncol. 2023; 15(3):101686.

PMID: 38114335 PMC: 10994748. DOI: 10.1016/j.jgo.2023.101686.


Healthcare delivery to elderly and unfit patients with breast disease and comorbidities under an outpatient regime: A report of a personal surgical technique named "Cut&Sew".

Rassu P Surg Open Sci. 2023; 16:49-57.

PMID: 37808422 PMC: 10550772. DOI: 10.1016/j.sopen.2023.09.012.


Acceptability of a companion patient guide to support expert consensus guidelines on surveillance mammography in older breast cancer survivors.

Freedman R, Revette A, Gagnon H, Perilla-Glen A, Kokoski M, Hussein S Breast Cancer Res Treat. 2022; 195(2):141-152.

PMID: 35908120 PMC: 9362353. DOI: 10.1007/s10549-022-06676-3.


Imaging Surveillance Options for Individuals With a Personal History of Breast Cancer: Expert Panel Narrative Review.

Lawson M, Herschorn S, Sprague B, Buist D, Lee S, Newell M AJR Am J Roentgenol. 2022; 219(6):854-868.

PMID: 35544374 PMC: 9691521. DOI: 10.2214/AJR.22.27635.


Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.

Aiello Bowles E, Ramin C, Buist D, Feigelson H, Weinmann S, Veiga L Breast Cancer Res Treat. 2022; 193(1):203-216.

PMID: 35275285 PMC: 10135399. DOI: 10.1007/s10549-022-06561-z.

References
1.
Smith B, Smith G, Hurria A, Hortobagyi G, Buchholz T . Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009; 27(17):2758-65. DOI: 10.1200/JCO.2008.20.8983. View

2.
Arias E . United States Life Tables, 2017. Natl Vital Stat Rep. 2020; 68(7):1-66. View

3.
Miller K, Nogueira L, Mariotto A, Rowland J, Yabroff K, Alfano C . Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; 69(5):363-385. DOI: 10.3322/caac.21565. View

4.
Schonberg M, Walter L . Talking about stopping cancer screening-not so easy. JAMA Intern Med. 2013; 173(7):532-3. DOI: 10.1001/jamainternmed.2013.3233. View

5.
Nguyen P, Taghian A, Katz M, Niemierko A, Abi Raad R, Boon W . Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008; 26(14):2373-8. DOI: 10.1200/JCO.2007.14.4287. View